Combination Therapy Using Cellcept and Rebif in RRMS - Related Studies

Combination Therapy Using Cellcept and Rebif in RRMS

This study is currently recruiting participants.

Study NCT00618527. Last updated on February 19, 2008. Information provided by Ohio State University

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Multiple Sclerosis

2	Additional conditions recognized in this trial
		Sclerosis

3	More general conditions related to this trial
		Autoimmune Diseases
		Autoimmune Diseases of the Nervous System
		Demyelinating Autoimmune Diseases, CNS
		Demyelinating Diseases
		Immune System Diseases
		Nervous System Diseases
		Pathologic Processes

4	Interventions listed in this trial
		mycophenalate mofetil (Cellcept)
		human interferon beta 1a (Rebif)

5	Additional drug interventions recognized in this trial
		Interferon beta 1a
		Interferon Type I, Recombinant
		Interferon-beta
		Interferons
		Mycophenolate mofetil

6	More general drug interventions related to this trial
		Adjuvants, Immunologic
		Angiogenesis Inhibitors
		Angiogenesis Modulating Agents
		Anti-Infective Agents
		Antineoplastic Agents
		Antiviral Agents
		Growth Inhibitors
		Growth Substances
		Immunologic Factors
		Immunosuppressive Agents
		Pharmacologic Actions
		Physiological Effects of Drugs
		Therapeutic Uses

7	Sponsors listed in this trial
		Ohio State University
		EMD Serono
		Pfizer